|
|
|
|
Pfizer reports more setbacks in drug tests: Three cancer treatments prove to be ineffective [The Day, New Lond
13--One week after announcing that a promising drug targeting Alzheimer's disease had failed to deliver hoped-for results, Pfizer Inc.said three potential cancer treatments had either failed or been terminated in late-stage studies. The New York-based drug...
|
|
|
Pfizer reports more setbacks in drug tests
Three cancer treatments prove to be ineffective One week after announcing that a promising drug targeting Alzheimer's disease had failed to deliver hoped-for results, Pfizer Inc.said three potential cancer treatments had either failed or been terminated in...
|
|
|
Pfizer says Sutent fails in breast cancer studies
6:46 PM EST Business News More>> NEW YORK (AP) - Pfizer Inc.said Thursday the cancer drug Sutent did not meet key goals in two late-stage studies focusing on advanced breast cancer. The drug is already sold as a treatment for advanced...
|
|
|
Late-Stage Cancer Misses Could Mean Advantage for Competitors
A double dose of disappointing Phase III data late last week from Pfizer Inc.and Genentech Inc. marked small setbacks for the big drugmakers but could be good news in the long run for their smaller biotech competitors. The failure of New York-based...
|
|
|
Late-Stage Cancer Misses Could Mean Advantage for Competitors
A double dose of disappointing Phase III data late last week from Pfizer Inc.and Genentech Inc. marked small setbacks for the big drugmakers but could be good news in the long run for their smaller biotech competitors. The failure of New York-based...
|
|
|
Business Briefing | Health: Setbacks for Pfizer on Cancer Treatments
Pfizer said two late-stage breast cancer trials involving its cancer drug Sutent failed to meet their goals and it has stopped a pivotal lung cancer trial of an experimental drug.Pfizer said outside monitors concluded that the Phase 3 trial of the lung...
|
|
|
Setbacks for Pfizer on Cancer Treatments
Pfizer said two late-stage breast cancer trials involving its cancer drug Sutent failed to meet their goals and it has stopped a pivotal lung cancer trial of an experimental drug.Pfizer said outside monitors concluded that the Phase 3 trial of the lung...
|
|
|
Pfizer Fails Again
Two of its trial drugs take a hit, and competitors are ready to pounce.Share this article: A- A A+ Related Articles Pfizer Fails Again The Next Big Opportunity for Big Pharma Is BRIC Should FDA Really Approve Byetta LAR? What Facet Brings to Abbott Animal...
|
|
|
Pfizer's sunitinib phase-3 trails for advanced breast cancer fails to meet primary endpoint
Pfizer Inc.announced that two phase-3 studies of Sutent (sunitinib malate) in advanced breast cancer did not meet their primary endpoints. The SUN 1064 phase 3 study of sunitinib in combination with docetaxel for the first-line treatment of patients...
|
|
|
Abbott, Pfizer lead drug stocks lower
Story Quotes Comments Screener AlertEmail Print BOSTON (MarketWatch) -- Abbott Laboratories paced drug stocks' fall Friday as shares of the medical products conglomerate lost ground on an analyst downgrade.Shares of Abbott /quotes/comstock/13*!abt/quotes/nls...
|
|
|
Two Phase 3 Trials of Sunitinib With Commonly Used Chemotherapies in Advanced Breast Cancer Did Not Meet The P
Detailed Results to be Presented at Future Medical Meeting NEW YORK--(BUSINESS WIRE)--Mar 11, 2010 - Pfizer Inc.announced today that two Phase 3 studies of Sutent (sunitinib malate) in advanced breast cancer did not meet their primary endpoints. The...
|
|
|
Sector Update: Health Care Shares Finish Lower On Disappointing Drug Trials, Consumer Data
3:11 EST Related Symbols: ABT, AMGN, ARNA, JNJ, MRK, PFE, PGNX PAGE TOOLS Text Size 03:11 PM Eastern Standard Time, 03/12/2010 (MidnightTrader) Dow Jones U.S.Health Care Index (DJUSHC) -1.66, (-0.50%), to 329.49 Top Health Care Stocks JNJ: -0.26% PFE: -1.16%...
|
|
|
Pfizer says two breast cancer drug studies fail
Pharmaceuticals Pfizer Inc Story Quotes Comments Screener (3) AlertEmail Print By Wallace Witkowski SAN FRANCISCO (MarketWatch) -- Pfizer Inc./quotes/comstock/13*!pfe/quotes/nls/pfe (PFE 17.08, -0.21, -1.21%) said late Thursday two late-stage studies of an...
|
|
|
Sector Update: Health Care Shares Lower as Pfizer Breast Cancer Drug Trials Falter
11:25 EST Related Symbols: ABT, AMGN, ARNA, JNJ, MRK, PFE, PGNX PAGE TOOLS Text Size 11:25 AM Eastern Standard Time, 03/12/2010 (MidnightTrader) Dow Jones U.S.Health Care Index (DJUSHC) -0.83, (-0.25%), to 330.32 Top Health Care Stocks JNJ: -0.19% PFE: -0.93...
|
|
|
09:58amMomentum drops on Wall Street
THE recent momentum in financial stocks ebbed, leaving the market in a narrow range as investors digested mixed readings of consumer spending and sentiment.Traders generally avoided big bets ahead of a packed economic calendar next week. But a few...
|
|
|
Pfizer Reveals its Disappointment Over its Study Results for Two Drugs
Pfizer Inc.outside monitors made an announcement, concluding that the Phase 3 trial of its experimental drug called figitumumab in patients with previously treated advanced non-small cell lung cancer was highly susceptible to post that the drug was effective...
|
|
|
Two Pfizer Cancer Drugs Fail Trials
Pfizer has discontinued the Phase III trial A4021018 (ADVIGO 1018), which examined the investigational compound figitumumab (CP-751,871) in combination with erlotinib as a second/third-line treatment in patients with previously treated advanced non...
|
|
|
09:58amMomentum drops on Wall Street
THE recent momentum in financial stocks ebbed, leaving the market in a narrow range as investors digested mixed readings of consumer spending and sentiment.Traders generally avoided big bets ahead of a packed economic calendar next week. But a few...
|
|
|
Momentum drops on Wall Street
THE recent momentum in financial stocks ebbed, leaving the market in a narrow range as investors digested mixed readings of consumer spending and sentiment.Traders generally avoided big bets ahead of a packed economic calendar next week. But a few...
|
|
|
MARKET SNAPSHOT: Stocks Rangebound As Financials Pull Back
financial stocks' recent momentum ebbed Friday, leaving the market in a narrow range as investors digested mixed readings of consumer spending and sentiment.Traders generally avoided big bets ahead of an even more packed economic calendar next week. But a...
|
|
|
Pfizer breast cancer drug fails in two studies
Business Financial Newswire - Pfizer's breast cancer drug Sutent (sunitinib malate) failed to meet its primary endpoints in two phase three trials, the firm said today (12 March).The SUN 1064 Phase 3 study of sunitinib in combination with docetaxel for...
|
|
|
Pfizer suffers late-stage cancer drug failures
Pfizer has suffered late-stage trial failures for Sutent and lung cancer candidate figitumumab.Kidney cancer drug Sutent (sunitinib) failed to meet its primary endpoints in two phase III trials that were testing it as a treatment for advanced HER...
|
|
|
Pfizer says clinical trials for Sutent did not meet expectations; halts additional cancer treatment study
NEW YORK (Mar.12) Two clinical trials of a Pfizer drug for treating advanced breast cancer have failed, Pfizer announced Thursday. The worlds largest drug maker said two phase 3 trials in which Sutent (sunitinib malate) was added to chemotherapy did...
|
|
|
UPDATE 2-Pfizer says Sutent breast cancer trials fail
* 2 Sutent breast cancer trials fail to meet goals * Figitumumab lung cancer trial stopped (Adds background, share price) LOS ANGELES, March 11 (Reuters) - Pfizer Inc <PFE.N> said on Thursday that two late-stage breast cancer trials involving its...
|
|
|
Pfizer reports negative results for Sutent trials in advanced breast cancer
Pfizer announced Thursday that two Phase 3 studies of Sutent (sunitinib) in advanced breast cancer did not meet their primary endpoints.The drugmaker stated that it nonetheless 'remains committed to the development programme' for the drug. The SUN...
|
